FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912651942> ?p ?o ?g. }

• W2912651942 endingPage "3151" @default.
• W2912651942 startingPage "3151" @default.
• W2912651942 abstract "Abstract Introduction: COMPLEMENT 2 is a phase III, randomized, open-label study, which compared the efficacy of ofatumumab (OFA) in combination with fludarabine and cyclophosphamide (FC) vs FC therapy alone in patients (pts) with relapsed chronic lymphocytic leukemia (CLL). In a previous interim analysis (2015) performed based on 194 progression-free survival (PFS) events, OFA+FC showed significant improvement of PFS and was well tolerated compared to FC in pts with relapsed CLL. Here, we report the 5-year follow-up of overall survival (OS) and safety profile of the drugs evaluated in this study. Methods: Based on stratification factors (number of prior CLL therapies and Binet stage), pts with relapsed CLL were randomized 1:1 to Arm A (OFA+FC) and Arm B (FC alone). Arm A received OFA intravenously (IV) (300 mg on day 1, cycle [c] 1; 1000 mg on day 8, c1; and 1000 mg on day 1, c2-6) in addition to FC (F [IV]: 25 mg/m2 and C [IV]: 250 mg/m2 on days 1-3, c1-6). Arm B received FC only. Pts who had achieved a complete response or partial response following at least 1 prior CLL therapy, but whose disease had progressed after >6 months (mo) were included in the present study. The primary endpoint was PFS. Key secondary endpoints were OS, time to next treatment (TTNT), and safety. During the primary analysis for PFS, all the type 1 error (1-sided alpha 0.025) was spent, resulting in no alpha remaining for inferential interpretation of the final analysis for OS. The final analysis results will be used for descriptive and supportive purposes only. Results: A total of 365 pts were randomly assigned to receive OFA+FC (n=183) or FC (n=182) in the final analysis. Overall, 119 (65%) and 102 (56%) pts completed the scheduled OFA+FC and FC treatments, respectively. Adverse events (AEs) were the main reason for treatment discontinuation in both treatment arms (50 [27%] pts in the OFA+FC arm and 52 [29%] in the FC arm). A total of 332 (91%) pts entered the follow-up phase, 172 (94%) from the OFA+FC arm and 160 (88%) from the FC arm. The follow-up phase for the OFA+FC and FC arms was approximately 41 mo and 23 mo, respectively. Baseline characteristics were similar in both arms. Median PFS was not assessed for the final analysis because the final results for the primary endpoint of PFS were reported as part of the primary analysis. PFS was 28.9 mo for OFA+FC and 18.8 mo for FC (hazard ratio [HR]=0.67, 95% confidence interval [CI]: 0.51, 0.88; p=0.0032). The final OS analysis was performed based on 82 events in the OFA+FC arm and 83 events in the FC arm. Median OS was 62.6 mo (95% CI: 44.58, NA) and 46.2 mo (95% CI: 37.72, 56.57) for the OFA+FC and FC arms, respectively (HR=0.80, 95% CI: 0.59, 1.09; p=0.143) (Figure 1). Median TTNT in the OFA+FC and FC arms was 53 mo and 40.1 mo, respectively (HR=0.77, 95% CI: 0.55, 1.08; p=0.114). As per the primary analysis, the overall response rate (95% CI) by independent review committee assessment (IRC) was 84% (77%, 89%) for OFA+FC and 68% (60%, 74%) for FC (p=0.0003). Other secondary endpoints (in mo) for OFA+FC vs FC were IRC-assessed median time to response (1 vs 1; HR=1.08, 95% CI: 0.85, 1.37; p=0.45), median duration of response (29.6 vs 24.9; HR=0.77, 95% CI: 0.56, 1.05; p=0.09), and median time to progression (42.1 vs 26.8; HR=0.63, 95% CI: 0.45, 0.87; p=0.004). All AEs and AEs of grade 3, 4, and 5 by preferred term (≥10%) are presented in Table 1. Serious drug-related AEs (≥2%) in the OFA+FC arm were pneumonia (8%), neutropenia and febrile neutropenia (7% each), and thrombocytopenia, pancytopenia, and pyrexia (2% each). Myelodysplastic syndrome was the most frequently reported secondary malignancy observed in ≥1% of pts (OFA+FC, 3 [2%]; FC, 2 [1%]). A total of 82 (45%) and 83 (47%) pts died during the study in the OFA+FC and FC arms, respectively; 2 (1%) and 6 (3%) died up to 60 days after the end of treatment, and 74 (41%) and 69 (39%) after >60 days. Three (2%) on-treatment deaths were reported in the OFA+FC arm and 4 (2%) in the FC arm. Conclusion: This final analysis confirmed the results of the primary analysis that addition of OFA to FC resulted in improvement of OS and TTNT by approximately 16 mo and 13 mo, respectively, compared to FC alone. Of note, the trend in the OS improvement seems to be maintained in the present long-term follow-up at 5 years. No new safety concerns have emerged in the long-term follow-up after treatment with OFA+FC, and the treatment was well tolerated. Disclosures Grosicki: Affimed: Research Funding. Lech-Maranda:Roche: Consultancy; Jansen-Cilag: Consultancy; Novartis: Consultancy; BMS: Consultancy; Amgen: Consultancy. Loscertales:Janssen: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria. Homenda:Janssen: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Rigel: Consultancy, Honoraria; Roche: Consultancy, Honoraria; Acerta: Consultancy, Honoraria. Blonski:Novartis: Consultancy. Stefanelli:Novartis: Employment, Equity Ownership. Vincent:Novartis: Employment. Banerjee:Novartis: Employment. Robak:AbbVie, Inc: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Gilead: Consultancy." @default.
• W2912651942 created "2019-02-21" @default.
• W2912651942 creator A5008703895 @default.
• W2912651942 creator A5021119940 @default.
• W2912651942 creator A5029918677 @default.
• W2912651942 creator A5031419975 @default.
• W2912651942 creator A5045927706 @default.
• W2912651942 creator A5048259851 @default.
• W2912651942 creator A5052049559 @default.
• W2912651942 creator A5061356652 @default.
• W2912651942 creator A5062322697 @default.
• W2912651942 creator A5072286696 @default.
• W2912651942 creator A5075091470 @default.
• W2912651942 creator A5076882576 @default.
• W2912651942 creator A5079452047 @default.
• W2912651942 creator A5087571749 @default.
• W2912651942 creator A5091376677 @default.
• W2912651942 date "2018-11-29" @default.
• W2912651942 modified "2023-10-02" @default.
• W2912651942 title "Long-Term Evaluation of Efficacy and Safety of Ofatumumab Added to Fludarabine & Cyclophosphamide in Subjects with Relapsed Chronic Lymphocytic Leukemia: Final Analysis of Complement 2 Trial" @default.
• W2912651942 doi "https://doi.org/10.1182/blood-2018-99-112139" @default.
• W2912651942 hasPublicationYear "2018" @default.
• W2912651942 type Work @default.
• W2912651942 sameAs 2912651942 @default.
• W2912651942 citedByCount "0" @default.
• W2912651942 crossrefType "journal-article" @default.
• W2912651942 hasAuthorship W2912651942A5008703895 @default.
• W2912651942 hasAuthorship W2912651942A5021119940 @default.
• W2912651942 hasAuthorship W2912651942A5029918677 @default.
• W2912651942 hasAuthorship W2912651942A5031419975 @default.
• W2912651942 hasAuthorship W2912651942A5045927706 @default.
• W2912651942 hasAuthorship W2912651942A5048259851 @default.
• W2912651942 hasAuthorship W2912651942A5052049559 @default.
• W2912651942 hasAuthorship W2912651942A5061356652 @default.
• W2912651942 hasAuthorship W2912651942A5062322697 @default.
• W2912651942 hasAuthorship W2912651942A5072286696 @default.
• W2912651942 hasAuthorship W2912651942A5075091470 @default.
• W2912651942 hasAuthorship W2912651942A5076882576 @default.
• W2912651942 hasAuthorship W2912651942A5079452047 @default.
• W2912651942 hasAuthorship W2912651942A5087571749 @default.
• W2912651942 hasAuthorship W2912651942A5091376677 @default.
• W2912651942 hasBestOaLocation W29126519421 @default.
• W2912651942 hasConcept C126322002 @default.
• W2912651942 hasConcept C141071460 @default.
• W2912651942 hasConcept C143998085 @default.
• W2912651942 hasConcept C168563851 @default.
• W2912651942 hasConcept C203092338 @default.
• W2912651942 hasConcept C2776694085 @default.
• W2912651942 hasConcept C2776755627 @default.
• W2912651942 hasConcept C2777063308 @default.
• W2912651942 hasConcept C2777938653 @default.
• W2912651942 hasConcept C2778461978 @default.
• W2912651942 hasConcept C2778714382 @default.
• W2912651942 hasConcept C2779015954 @default.
• W2912651942 hasConcept C2779263901 @default.
• W2912651942 hasConcept C2911091166 @default.
• W2912651942 hasConcept C61943457 @default.
• W2912651942 hasConcept C71924100 @default.
• W2912651942 hasConcept C90924648 @default.
• W2912651942 hasConceptScore W2912651942C126322002 @default.
• W2912651942 hasConceptScore W2912651942C141071460 @default.
• W2912651942 hasConceptScore W2912651942C143998085 @default.
• W2912651942 hasConceptScore W2912651942C168563851 @default.
• W2912651942 hasConceptScore W2912651942C203092338 @default.
• W2912651942 hasConceptScore W2912651942C2776694085 @default.
• W2912651942 hasConceptScore W2912651942C2776755627 @default.
• W2912651942 hasConceptScore W2912651942C2777063308 @default.
• W2912651942 hasConceptScore W2912651942C2777938653 @default.
• W2912651942 hasConceptScore W2912651942C2778461978 @default.
• W2912651942 hasConceptScore W2912651942C2778714382 @default.
• W2912651942 hasConceptScore W2912651942C2779015954 @default.
• W2912651942 hasConceptScore W2912651942C2779263901 @default.
• W2912651942 hasConceptScore W2912651942C2911091166 @default.
• W2912651942 hasConceptScore W2912651942C61943457 @default.
• W2912651942 hasConceptScore W2912651942C71924100 @default.
• W2912651942 hasConceptScore W2912651942C90924648 @default.
• W2912651942 hasIssue "Supplement 1" @default.
• W2912651942 hasLocation W29126519421 @default.
• W2912651942 hasOpenAccess W2912651942 @default.
• W2912651942 hasPrimaryLocation W29126519421 @default.
• W2912651942 hasRelatedWork W1978820133 @default.
• W2912651942 hasRelatedWork W2024097666 @default.
• W2912651942 hasRelatedWork W2094106544 @default.
• W2912651942 hasRelatedWork W2103857518 @default.
• W2912651942 hasRelatedWork W2124575836 @default.
• W2912651942 hasRelatedWork W2500213562 @default.
• W2912651942 hasRelatedWork W2586087638 @default.
• W2912651942 hasRelatedWork W2590462942 @default.
• W2912651942 hasRelatedWork W2597391618 @default.
• W2912651942 hasRelatedWork W3190055377 @default.
• W2912651942 hasVolume "132" @default.
• W2912651942 isParatext "false" @default.
• W2912651942 isRetracted "false" @default.
• W2912651942 magId "2912651942" @default.
• W2912651942 workType "article" @default.